# A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

> **NCT02314819** · PHASE3 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 416 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** fruquintinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02314819
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-01
- **Final completion:** 2017-01-17
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314819, "A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02314819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*